Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCTNASDAQ:BLUEOTCMKTS:CSLLYNYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$11.51+5.1%$12.04$8.04▼$45.00$312.16M2.36449,044 shs172,500 shsBLUEbluebird bio$3.75+1.6%$4.23$3.56▼$28.60$36.71M0.27348,618 shs55,236 shsCSLLYCSL$78.02-3.6%$78.64$70.22▼$109.00$75.56B0.7993,928 shs52,997 shsNVSNovartis$110.55-1.0%$110.32$96.06▼$120.92$233.53B0.61.56 million shs1.07 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-2.58%-14.52%+20.46%-36.67%-60.27%BLUEbluebird bio-3.75%-9.44%-22.54%-44.77%-81.71%CSLLYCSL-3.61%-2.91%+6.37%-8.81%-15.53%NVSNovartis+0.96%-1.29%+8.63%+4.53%+12.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics2.6715 of 5 stars4.60.00.00.02.02.50.6BLUEbluebird bio2.4661 of 5 stars3.14.00.00.01.21.71.3CSLLYCSL1.0814 of 5 stars0.03.01.70.02.00.01.3NVSNovartis2.2848 of 5 stars2.03.02.50.02.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.13Buy$59.20414.34% UpsideBLUEbluebird bio 2.25Hold$44.601,089.33% UpsideCSLLYCSL 4.00Strong BuyN/AN/ANVSNovartis 2.00Hold$123.3811.60% UpsideCurrent Analyst Ratings BreakdownLatest CSLLY, NVS, BLUE, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025NVSNovartisBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.003/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/7/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$63.00 ➝ $60.003/7/2025ARCTArcturus TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/7/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$58.00 ➝ $50.002/24/2025BLUEbluebird bioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $5.002/24/2025BLUEbluebird bioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral2/21/2025BLUEbluebird bioBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$138.39M2.26N/AN/A$10.42 per share1.10BLUEbluebird bio$83.81M0.44N/AN/A$35.59 per share0.11CSLLYCSL$14.80B5.11$3.75 per share20.80$20.07 per share3.89NVSNovartis$53.22B4.39$11.02 per share10.03$21.59 per share5.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/12/2025 (Estimated)BLUEbluebird bio-$211.91M-$45.54N/AN/AN/A-565.74%-322.46%-53.17%N/ACSLLYCSL$2.64BN/A0.0019.081.59N/AN/AN/AN/ANVSNovartis$11.94B$6.4018.8012.551.7023.56%37.24%15.85%7/17/2025 (Estimated)Latest CSLLY, NVS, BLUE, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.10N/AN/AN/A$25.64 millionN/A4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.716.21%N/AN/A N/ABLUEbluebird bioN/AN/AN/AN/AN/ACSLLYCSL$1.201.54%N/AN/AN/ANVSNovartis$2.592.34%+5.34%40.47%N/ALatest CSLLY, NVS, BLUE, and ARCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.764.76BLUEbluebird bio0.370.510.33CSLLYCSL0.582.180.97NVSNovartis0.481.040.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BLUEbluebird bio87.43%CSLLYCSL0.03%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%BLUEbluebird bio1.40%CSLLYCSLN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCSLLYCSL30,000968.42 millionN/ANot OptionableNVSNovartis101,7002.11 billion2.04 billionOptionableCSLLY, NVS, BLUE, and ARCT HeadlinesRecent News About These CompaniesBenjamin Edwards Inc. Has $3.60 Million Stock Position in Novartis AG (NYSE:NVS)May 8 at 5:20 AM | marketbeat.comAptus Capital Advisors LLC Raises Stock Position in Novartis AG (NYSE:NVS)May 8 at 4:57 AM | marketbeat.comBridgefront Capital LLC Invests $842,000 in Novartis AG (NYSE:NVS)May 7 at 7:15 AM | marketbeat.comCastlekeep Investment Advisors LLC Makes New $109.74 Million Investment in Novartis AG (NYSE:NVS)May 7 at 6:29 AM | marketbeat.comChapman Financial Group LLC Purchases New Holdings in Novartis AG (NYSE:NVS)May 7 at 6:28 AM | marketbeat.comIncyte, Novartis agree to settle long-running Jakafi royalty dispute just before trialMay 7 at 1:28 AM | fiercepharma.comNovartis AG (NYSE:NVS) Shares Sold by Price T Rowe Associates Inc. MDMay 6 at 4:04 AM | marketbeat.comBioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology ExpansionMay 5 at 3:49 PM | benzinga.comNovartis (NVS) is a Great Momentum Stock: Should You Buy?May 5 at 1:05 PM | zacks.comWhy Novartis (NVS) is a Great Dividend Stock Right NowMay 5 at 12:50 PM | zacks.comFederal Circuit Keeps FDA Hold in MSN-Novartis Drug-Patent FightMay 5 at 11:41 AM | news.bloomberglaw.comBioNTech says Novartis executive Zapata-Gomez to become CFOMay 5 at 6:34 AM | reuters.comNovartis AG (NYSE:NVS) Shares Sold by Mercer Global Advisors Inc. ADVMay 5 at 5:36 AM | marketbeat.comHutner Capital Management Inc. Purchases 3,324 Shares of Novartis AG (NYSE:NVS)May 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires Shares of 62,418 Novartis AG (NYSE:NVS)May 4, 2025 | marketbeat.comNovartis AG (NYSE:NVS) Shares Purchased by Lido Advisors LLCMay 4, 2025 | marketbeat.comNorthern Trust Corp Purchases 399,862 Shares of Novartis AG (NYSE:NVS)May 4, 2025 | marketbeat.comVoya Investment Management LLC Sells 15,665 Shares of Novartis AG (NYSE:NVS)May 4, 2025 | marketbeat.comNovartis AG (NOVN) Receives a Hold from Berenberg BankMay 3, 2025 | theglobeandmail.comBMS scales back at former Novartis plant, shifting cell therapy vector production to MAMay 2, 2025 | fiercepharma.comNovartis to Acquire Regulus TherapeuticsMay 2, 2025 | pharmexec.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBy Jea Yu | April 21, 2025View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockHidden Gems: 3 Quiet Stocks With Loud PotentialBy Nathan Reiff | April 23, 2025View Hidden Gems: 3 Quiet Stocks With Loud Potential Microsoft: A Blend of Growth and Value Amid Tariff ConcernsBy Chris Markoch | April 15, 2025View Microsoft: A Blend of Growth and Value Amid Tariff ConcernsCSLLY, NVS, BLUE, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$11.51 +0.56 (+5.11%) As of 01:18 PM EasternArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.bluebird bio NASDAQ:BLUE$3.75 +0.06 (+1.63%) As of 01:18 PM Easternbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.CSL OTCMKTS:CSLLY$78.02 -2.92 (-3.61%) As of 05/7/2025 03:58 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Novartis NYSE:NVS$110.55 -1.15 (-1.03%) As of 01:17 PM EasternNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
